Free Trial
NASDAQ:PYXS

Pyxis Oncology Q4 2024 Earnings Report

Pyxis Oncology logo
$1.24 +0.01 (+0.81%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.24 0.00 (-0.40%)
As of 05/27/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Pyxis Oncology Revenue Results

Actual Revenue
$16.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 18, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Pyxis Oncology's Q1 2025 earnings is scheduled for Wednesday, August 13, 2025

Pyxis Oncology Earnings Headlines

Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright
HC Wainwright Comments on Pyxis Oncology Q1 Earnings
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS), a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

View Pyxis Oncology Profile

More Earnings Resources from MarketBeat